Company Overview of Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
1030 Massachusetts Avenue
Cambridge, MA 02138
Founded in 2012
Key Executives for Jounce Therapeutics, Inc.
Compensation as of Fiscal Year 2014.
Jounce Therapeutics, Inc. Key Developments
Jounce Therapeutics, Inc. Appoints Deborah Law, D. Phil., to the Position of Chief Scientific Officer
Jan 8 15
Jounce Therapeutics, Inc. announced the appointment of Deborah Law, D. Phil., to the position of chief scientific officer. Dr. Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology. Dr. Law joins Jounce from Merck, where she most recently served as vice president of Therapy Area Biology for Immunology, Oncology and Immunomodulators. In this role, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic. Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics.
Jounce Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM
Jan 6 15
Jounce Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Richard Murray, Chief Executive Officer.
Jounce Therapeutics, Inc. Announces Executive Changes
Jul 10 14
Jounce Therapeutics, Inc. announced the appointment of Richard Murray, Ph.D., to chief executive officer. Dr. Murray brings to Jounce more than two decades of experience building biologics R&D capabilities and moving exciting science through development for both startup biotechnology and large pharmaceutical companies. Dr. Murray succeeds interim CEO Cary Pfeffer, M.D., who will assume the position of chairman of Jounce's board of directors. Dr. Murray joins Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research, and was a member of the Merck Research Laboratories (MRL) leadership team.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|